Jazz Pharmaceuticals PLC

JAZZ: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|@@LOCK|M>pLOCK|&SMVhD

Jazz: Ziihera's Strong Data and Approval in HER2-Positive Gastroesophageal Cancer Improves Outlook

Jazz received US approval of Ziihera as a first-line treatment of all HER2-positive advanced gastroesophageal adenocarcinoma, or GEA, used in addition to chemotherapy, with or without Tevimbra. Additional phase 3 data further reinforced its survival advantage over Herceptin with longer follow-up.

Sponsor Center